The P-I-E-N-O Parkinsn's List Drug Database

Mail converted by MHonArc 2.6.10

PIENO Google Custom Search

Site Hosting donated by & Grant from The Parkinson Alliance

cabergoline / Destinex^TM

ANTIPARKINSON:

Dopamine agonist

Description: Cabergoline is a long-acting dopamine agonist under investigation in Italy. Actions: agonism at dopamine receptors suppresses prolactin secretion, shrinks prolactinomas, and restores gonadal function.

Uses: undergoing review for treatment of hyperprolactinemic amenorrhea.

Distinguishing Features: requires only two doses per week compared with bromocriptine which must be dosed 2-3 times/day; cabergoline was found superior to bromocriptine in treatment of hyperprolactinemic amenorrhea and cabergoline caused less nausea.

Major Adverse Reactions: nausea/vomiting, headache, vertigo, dyspepsia.

Usual Adult Dose: doses of 0.5-1 mg PO twice weekly have been studied. Once weekly dosing has also been successful.

Manufacturer: Farmitalia Carlo Erba, Milan, Italy. Status: unclear at this time (unable to contact manufacturer 4/12/95).

References: *comparative study: Webster J et al. N Engl J Med 1994;331:904- 9. *comparative study: Ferrari C et al. J Clin Endocrinol Metab 1989;68:1202-6.

The P-I-E-N-O Parkinsn's List Drug Database Index

John Cottingham is the webmaster of this site.